The oncology compound Stivarga (regorafenib) from Bayer has been approved by the European Commission (EC) for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib. The approval of Stivarga in GIST is based on results from the pivotal Phase III study (GRID) that demonstrated a statistically significant improvement in progression-free survival (PFS) compared to placebo in patients with GIST whose disease had progressed after prior treatments. Stivarga is already approved in the EU for the treatment of patients with metastatic colorectal cancer.

For more details, go to: http://www.news.bayer.com/baynews/baynews.nsf/id/Stivarga-regorafenib-Bayer-Approved-European-Union-Treatment-Gastrointestinal-Stromal-Tumors?OpenDocument&sessionID=1406750626